| __timestamp | Bio-Techne Corporation | Biogen Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 106352000 | 1171036000 |
| Thursday, January 1, 2015 | 144969000 | 1240400000 |
| Friday, January 1, 2016 | 162364000 | 1478700000 |
| Sunday, January 1, 2017 | 188462000 | 1630000000 |
| Monday, January 1, 2018 | 210850000 | 1816300000 |
| Tuesday, January 1, 2019 | 240515000 | 1955400000 |
| Wednesday, January 1, 2020 | 255497000 | 1805200000 |
| Friday, January 1, 2021 | 298182000 | 2109700000 |
| Saturday, January 1, 2022 | 349103000 | 2278300000 |
| Sunday, January 1, 2023 | 366887000 | 2533400000 |
| Monday, January 1, 2024 | 389335000 | 0 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, understanding cost structures is crucial. This analysis compares the cost of revenue for Biogen Inc. and Bio-Techne Corporation from 2014 to 2023. Biogen Inc., a leader in neurological therapies, consistently reported higher costs, peaking at approximately $2.53 billion in 2023, reflecting a 116% increase from 2014. In contrast, Bio-Techne Corporation, known for its life sciences tools, saw a 266% rise in costs, reaching around $389 million in 2023. This disparity highlights Biogen's larger scale and investment in R&D. Notably, 2024 data for Biogen is missing, suggesting potential reporting delays or strategic shifts. Such insights are vital for investors and stakeholders to gauge operational efficiency and strategic direction in the biotech sector.
Novo Nordisk A/S vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Novartis AG vs Biogen Inc.: Efficiency in Cost of Revenue Explored
Takeda Pharmaceutical Company Limited vs Biogen Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Biogen Inc. and Incyte Corporation
Cost of Revenue: Key Insights for Biogen Inc. and Viatris Inc.
Cost of Revenue: Key Insights for Biogen Inc. and Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Bio-Techne Corporation and BioMarin Pharmaceutical Inc.
Bio-Techne Corporation vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Bio-Techne Corporation and Amphastar Pharmaceuticals, Inc.'s Expenses
Bio-Techne Corporation vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Bio-Techne Corporation vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Bio-Techne Corporation and BioCryst Pharmaceuticals, Inc.